Biopharmaceutical contract manufacturing market is projected to grow at an annualized rate of ~8%, till 2030 Knowpia

Roots Analysis has done a detailed study on Biopharma Contract Manufacturing Market (3^rd Edition), 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 750+ page report, which features 200+ figures and 250+ tables, please visit this https://www.rootsanalysis.com/reports/250/request-sample.html

Key Market Insights

§ Over 235 companies worldwide claim to offer contract manufacturing services for various types of biopharmaceutical drug / therapy products.

§ The market landscape is highly fragmented featuring the presence of both established players and new entrants; majority of biopharmaceutical CMOs are based in the developed geographies.

§ Case study: CMOs focusing on niche biologic markets, primarily novel product candidates for which in-house biomanufacturing expertise is low, are likely to experience significant growth in the coming years.

§ The installed global contract manufacturing capacity, spread across various geographies, is currently estimated to be over 4.5 million liters.

§ The demand for contract manufacturing services is expected to rise across different therapeutic areas; closer inspection of available capacity and expected utilization trend are required to optimize supply parameters.

§ With over 450 deals inked in the past six years, there has been a surge in the partnership activity; majority of the collaborations have been signed for the development and manufacturing of cell therapies and antibodies.

§ In order to cater the increasing demand for biologics, stake holders are actively expanding their existing capabilities; this is evident from the various acquisitions that have recently been reported.

§ We expect the developers to continue to outsource their manufacturing operations in the short to mid-term, resulting in an annualized growth rate of more than 8%.

§ In the long term, the projected opportunity is anticipated to be well distributed across various types of expression systems used for biomanufacturing, scale of operation and size of contract service providers

For more information, please visit https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html

Table of Contents

1. PREFACE

1.1. Scope of the Report

1.2. Research Methodology

1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Context and Background

3.2. An Overview of Biopharmaceuticals

3.3. Biopharmaceutical Manufacturing

3.3.1. Types of Expression Systems

3.3.1.1. Bacterial Expression Systems

3.3.1.2. Yeast Expression Systems

3.3.1.3. Fungal Expression Systems

3.3.1.4. Insect Expression Systems

3.3.1.5. Plant Expression Systems

3.3.1.6. Mammalian Expression Systems

3.3.2. Manufacturing Steps

3.3.2.1. Upstream Processing

3.3.2.2. Downstream Processing

3.4. An Overview of Contract Manufacturing

3.5. Need for Outsourcing in the Biopharmaceutical Industry

3.6. Commonly Outsourced Operations in the Biopharmaceutical Industry

3.7. Basic Guidelines for Selecting a CMO Partner

3.8. Advantages of Outsourcing Manufacturing Services

3.9. Risks and Challenges Associated with Biopharmaceutical Contract Manufacturing

3.10. Concluding Remarks

4. COMPETITIVE LANDSCAPE

4.1. Chapter Overview

4.2. Biopharmaceuticals Contract Manufacturers: Overall Market Landscape

4.2.1. Analysis by Size of Employee Base

4.2.2. Analysis by Location of Headquarters

4.2.3. Analysis by Year of Establishment

4.2.4. Analysis by Location of Manufacturing Facilities

4.2.5. Analysis by Type of Biologics Manufactured

4.2.6. Analysis by Scale of Operation

4.2.7. Analysis by Expression Systems

4.2.8. Analysis by Type of Bioreactor and Modes of Operation

4.2.9. Analysis by Biomanufacturing Capacity

4.2.10. Analysis by Packaging Form

4.3. Concluding Remarks

5. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN NORTH AMERICA

5.1. Chapter Overview

5.2. Biopharmaceutical Outsourcing in the US: Regulatory Scenario

5.2.1. Impact of Current Political Situation

5.3. Leading Biopharma CMOs in North America

5.3.1. AMRI (OsoBio)

5.3.1.1. Company Overview

5.3.1.2. Services Portfolio

5.3.1.3. Financial Information

5.3.1.4. Manufacturing Facilities

5.3.1.5. Partnerships

5.3.1.6. Recent Developments

5.3.1.7. Future Outlook

5.3.2. Baxter BioPharma Solutions

5.3.2.1. Company Overview

5.3.2.2. Services Portfolio

5.3.2.3. Financial Information

5.3.2.4. Manufacturing Facilities

5.3.2.5. Partnerships

5.3.2.6. Recent Developments

5.3.2.7. Future Outlook

5.3.3. Catalent Biologics (Catalent Pharma Solutions)

5.3.3.1. Company Overview

5.3.3.2. Services Portfolio

5.3.3.3. Financial Information

5.3.3.4. Manufacturing Facilities

5.3.3.5. Partnerships

5.3.3.6. Recent Developments

5.3.3.7. Future Outlook

5.3.4. Cytovance Biologics

5.3.4.1. Company Overview

5.3.4.2. Services Portfolio

5.3.4.3. Partnerships

5.3.4.4. Recent Developments

5.3.4.5. Future Outlook

5.3.5. Patheon

5.3.5.1. Company Overview

5.3.5.2. Services Portfolio

5.3.5.3. Financial Information

5.3.5.4. Manufacturing Facilities

5.3.5.5. Partnerships

5.3.5.6. Recent Developments

5.3.5.7. Future Outlook

5.3.6. Piramal Pharma Solutions

5.3.6.1. Company Overview

5.3.6.2. Services Portfolio

5.3.6.3. Financial Information

5.3.6.4. Facilities

5.3.6.5. Partnerships

5.3.6.6. Recent Developments

5.3.6.7. Future Outlook

6. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN EUROPE

6.1. Chapter Overview

6.2. Biopharmaceutical Outsourcing in Europe: Regulatory Scenario

6.3. Leading Biopharmaceutical CMOs in Europe

6.3.1. 3P Biopharmaceuticals

6.3.1.1. Company Overview

6.3.1.2. Services Portfolio

6.3.1.3. Manufacturing Facilities

6.3.1.4. Partnerships

6.3.1.5. Recent Developments

6.3.1.6. Future Outlook

6.3.2. Boehringer Ingelheim BioXcellence™

6.3.2.1. Company Overview

6.3.2.2. Services Portfolio

6.3.2.3. Financial Information

6.3.2.4. Manufacturing Facilities

6.3.2.5. Partnerships

6.3.2.6. Recent Developments

6.3.2.7. Future Outlook

6.3.3. Celonic

6.3.3.1. Company Overview

6.3.3.2. Services Portfolio

6.3.3.3. Manufacturing Facilities

6.3.3.4. Partnerships

6.3.3.5. Recent Developments

6.3.3.6. Future Outlook

6.3.4. FUJIFILM Diosynth Biotechnologies

6.3.4.1. Company Overview

6.3.4.2. Services Portfolio

6.3.4.3. Financial Information

6.3.4.4. Manufacturing Capabilities

6.3.4.5. Partnerships

6.3.4.6. Recent Developments

6.3.4.7. Future Outlook

6.3.5. LFB Group

6.3.5.1. Company Overview

6.3.5.2. Services Portfolio

6.3.5.3. Financial Information

6.3.5.4. Manufacturing Facilities

6.3.5.5. Partnerships

6.3.5.6. Recent Developments

6.3.5.7. Future Outlook

6.3.6. Lonza

6.3.6.1. Company Overview

6.3.6.2. Services Portfolio

6.3.6.3. Financial Information

6.3.6.4. Manufacturing Facilities

6.3.6.5. Partnerships

6.3.6.6. Recent Developments

6.3.6.7. Future Outlook

6.3.7. Menarini Biotech

6.3.7.1. Company Overview

6.3.7.2. Services Portfolio

6.3.7.3. Partnerships

6.3.7.4. Future Outlook

6.3.8. Novasep

6.3.8.1. Company Overview

6.3.8.2. Services Portfolio

6.3.8.3. Financial Information

6.3.8.4. Partnerships

6.3.8.5. Recent Developments

6.3.8.6. Future Outlook

6.3.9. Rentschler BioPharma

6.3.9.1. Company Overview

6.3.9.2. Services Portfolio

6.3.9.3. Manufacturing Facilities

6.3.9.4. Partnerships

6.3.9.5. Recent Developments

6.3.9.6. Future Outlook

7. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN ASIA PACIFIC AND THE REST OF THE WORLD

7.1. Chapter Overview

7.2. Biopharmaceutical Contract Manufacturing in China

7.2.1. Biopharmaceutical Outsourcing in China: Regulatory Scenario

7.2.2. Challenges Faced while Outsourcing to China

7.3. Biopharmaceutical CMOs in China

7.3.1. AutekBio

7.3.1.1. Company Overview

7.3.1.2. Services Portfolio

7.3.1.3. Manufacturing Facilities

7.3.1.4. Future Outlook

7.3.2. WuXi AppTec (WuXi Biologics)

7.3.2.1. Company Overview

7.3.2.2. Services Portfolio

7.3.2.3. Financial Information

7.3.2.4. Manufacturing Facilities

7.3.2.5. Partnerships

7.3.2.6. Recent Developments

7.3.2.7. Future Outlook

7.4. Biopharmaceutical Contract Manufacturing in India

7.4.1. Biopharmaceutical Outsourcing in India: Regulatory Scenario

7.4.2. Challenges Faced while Outsourcing to India

7.5. Biopharmaceutical CMOs in India

7.5.1. Intas Pharmaceuticals

7.5.1.1. Company Overview

7.5.1.2. Services Portfolio

7.5.1.3. Financial Information

7.5.1.4. Manufacturing Facilities

7.5.1.5. Future Outlook

7.5.2. Kemwell Biopharma

7.5.2.1. Company Overview

7.5.2.2. Services Portfolio

7.5.2.3. Manufacturing Facilities

7.5.2.4. Partnerships

7.5.2.5. Recent Developments

7.5.2.6. Future Outlook

7.5.3. Shasun Pharmaceuticals

7.5.3.1. Company Overview

7.5.3.2. Services Portfolio

7.5.3.3. Financial Information

7.5.3.4. Future Outlook

7.5.5. Syngene

7.5.5.1. Company Overview

7.5.5.2. Services Portfolio

7.5.5.3. Financial Information

7.5.5.4. Manufacturing Facilities

7.5.5.5. Partnerships

7.5.5.6. Recent Developments

7.5.5.7. Future Outlook

7.6. Biopharmaceutical Contract Manufacturing in Japan

7.6.1. Biopharmaceutical Outsourcing in Japan: Regulatory Scenario

7.6. Biopharmaceutical CMOs in Japan

7.6.1. Asahi Glass

7.6.1.1. Company Overview

7.6.1.2. Services Portfolio

7.6.1.3. Financial Information

7.6.1.4. Manufacturing Facilities

7.6.1.5. Partnerships

7.7.1.6. Recent Developments

7.7.1.7. Future Outlook

7.7. Biopharmaceutical Contract Manufacturing in South Korea

7.7.1. Biopharmaceutical Outsourcing in South Korea: Regulatory Scenario

7.7. Biopharmaceutical CMOs in South Korea

7.7.1. DM Bio

7.7.1.1. Company Overview

7.7.1.2. Services Portfolio

7.7.1.3. Manufacturing Facilities

7.7.1.4. Future Outlook

7.7.2. Samsung BioLogics

7.7.2.1. Company Overview

7.7.2.2. Services Portfolio

7.7.2.3. Financial Information

7.7.2.4. Manufacturing Facilities

7.7.2.5. Partnerships

7.7.2.6. Recent Developments

7.7.2.7. Future Outlook

7.8. Biopharmaceutical Contract Manufacturing in Australia

7.8.1. Biopharmaceutical Outsourcing in Australia: Regulatory Scenario

7.8. Biopharmaceutical CMOs in Australia

7.8.2. Cell Therapies

7.8.2.1. Company Overview

7.8.2.2. Services Portfolio

7.8.2.3. Manufacturing Facilities

7.8.2.4. Partnerships

7.8.2.5. Recent Developments

7.8.2.6. Future Outlook

7.8.3. Luina Bio

7.8.3.1. Company Overview

7.8.3.2. Services Portfolio

7.8.3.3. Manufacturing Facilities

7.8.3.4. Partnerships

7.8.3.5. Future Outlook

8. NICHE BIOPHARMACEUTICAL SECTORS

8.1. Chapter Overview

8.2. Antibody Drug Conjugates

8.2.1. Introduction

8.2.1.1. Manufacturing Process

8.2.1.2. Key Technologies and Technology Providers

8.2.2. Pipeline Analysis

8.2.2.1. ADC Pipeline: Marketed and Clinical Molecules

8.2.2.2. ADC Pipeline: Preclinical and Discovery Stage Molecules

8.2.2.3. ADC Manufacturing: Key Challenges

8.3. Bispecific Antibodies

8.3.1. Introduction

8.3.1.1. The Bispecific Advantage

8.3.2. Pipeline Analysis

8.3.3. Bispecific Antibody Technology Providers

8.3.4. Contract Manufacturing Scenario

8.4. Cell Therapies

8.4.1. Introduction

8.4.2. Current Market Landscape

8.4.3. Cell Therapy Manufacturing

8.4.4. Cell Therapy Manufacturing Models

8.4.4.1. Centralized Manufacturing Model

8.4.4.2. Decentralized Manufacturing Model

8.4.5. Cell Therapy Manufacturing: Key Challenges and Growth Drivers

8.4.6. Important Factors for Cell Therapy Manufacturing

8.4.6.1. Cell Characterization

8.4.6.2. Cost of Goods

8.4.7. Contract Manufacturing Scenario

8.4.7.1. Analysis by Type of Cells Manufactured

8.4.7.2. Analysis by Scale of Operation

8.5. Gene Therapy

8.5.1. Introduction

8.5.2. Gene Therapy: Pipeline Analysis

8.5.2.1. Analysis by Phase of Development

8.5.2.2. Analysis by Type of Vector

8.5.2.3. Analysis by Therapeutic Area

8.5.3. Contract Manufacturing Market Landscape

8.5.3.1. Analysis by Location

8.5.3.2. Analysis by Type of Viral Vector

8.5.3.3. Analysis by Scale of Production

8.6. Plasmid DNA

8.6.1. Introduction

8.6.2. Contract Manufacturing Market Landscape

8.6.3. Analysis by Location of Manufacturing Facility

8.6.4. Analysis by Scale of Production

9. CASE STUDY: OUTSOURCING OF BIOSIMILARS

9.1. Chapter Overview

9.2. Biosimilars: An Introduction

9.3. Biosimilars: Development Stages

9.4. Regulatory Requirements for Licensing of Biosimilars

9.5. Need for Outsourcing Biosimilar Development and Manufacturing

9.6. Impact of Biosimilars on the Global Contract Manufacturing Market

9.6.1. Region-wise Distribution of Biosimilar Development / Manufacturing Activity

9.7. List of Biosimilars Contract Manufacturing Service Provider

9.8. Challenges Associated with Biosimilar Outsourcing

10. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULE DRUGS / THERAPIES

10.1. Chapter Overview

10.2. Small Molecule and Large Molecule Drugs / Therapies

10.2.1. Comparison of General Characteristics

10.2.2. Comparison of Key Specifications

10.2.3. Comparison of Manufacturing Processes

10.2.4. Comparison of Key Manufacturing Challenges

11. CASE STUDY ON IN-HOUSE MANUFACTURING

11.1. Chapter Overview

11.2. In-House Manufacturing

11.2.1. Benefits Associated with In-House Manufacturing

11.2.2. Risks Associated with In-House Manufacturing

11.3. Outsourcing in the Biomanufacturing Industry

11.3.1. Types of Outsourcing Partners

11.4. Manufacturing Approaches Used for Approved Biologics (2016-2018)

11.4.1. Approved Biologics: Distribution by Size of Type of Manufacturing Approach

11.4.2. Approved Biologics: Distribution by Size of Developer and Type of Biologic

11.5. Choosing the Right Strategy: In-House Manufacturing versus Outsourcing

12. COLLABORATIONS

12.1. Chapter Overview

12.2. Partnership Models

12.3. Biopharmaceutical Contract Manufacturing: List of Partnerships and Collaborations

12.3.1. Analysis by Year of Partnerships

12.3.2. Analysis by Type of Partnerships

12.3.2.1. Year-Wise Trend of Product-based Agreements

12.3.2.2. Year-Wise Trend of Process-based Agreements

12.3.2.3. Year-Wise Trend of Licensing Agreements

12.3.2.4. Year-Wise Trend of Co-service Agreements / Ventures

12.3.2.5. Year-Wise Trend of R&D Agreements

12.3.2.6. Year-Wise Trend of Out-sourcing Services Agreements

12.3.3. Analysis by Focus Area

12.3.4. Analysis by Type of Biologics

12.3.4.1. Analysis by Type of Biologic and Type of Partnership Model

12.3.4.2. Analysis of Cell Therapy-related Deals by Year and Type of Partnership Model

12.3.4.3. Analysis of Monoclonal Antibody-related Deals by Year and Type of Partnership Model

12.3.4.4. Analysis of Vaccine-related Deals by Year and Type of Partnership Model

12.3.4.5. Analysis of Protein-related Deals by Year and Type of Partnership Model

12.3.4.6. Analysis of Antibody Drug Deals by Year and Type of Partnership Model

12.3.4.7. Analysis of Vector-related Deals by Year and Type of Partnership Model

12.3.4.8. Analysis of Gene Therapy-related Deals by Year and Type of Partnership Model

12.3.4.9. Analysis of Biosimilar-related Deals by Year and Type of Partnership Model

12.3.4.10. Analysis of Other Biologic-related Deals by Type of Partnership Model

12.3.4.11. Analysis by Type of Biologics and Geography

12.3.5. Analysis by Therapeutic Area

12.3.6. Analysis of Most Active Players by Number of Partnerships

12.3.7. Regional Analysis

12.3.7.1. Intercontinental and Intracontinental Agreements

12.4. Mergers and Acquisitions

12.4.1. Acquisitions Models

12.4.2. Biopharmaceutical Contract Manufacturing: Mergers and Acquisitions

12.4.3. Cumulative Year-wise Trend

12.4.4. Analysis by Type of Acquisition

12.4.5. Geographical Activity

12.4.5.1. Mergers and Acquisitions: Continent-wise Distribution

12.4.5.2. Mergers and Acquisitions: Country-wise Distribution

12.4.5.3. Mergers and Acquisitions: Intercontinental and Intracontinental Deals

12.4.6. Most Active Acquirers: Analysis by Number of Acquisitions

12.4.7 Mergers and Acquisitions: Distribution by Key Value Drivers and Type of Biologics

12.4.7.1. Mergers and Acquisitions: Analysis by Key Value Drivers

12.4.7.2. Mergers and Acquisitions: Analysis by Key Value Drivers and Year of Acquisition

12.4.7.3. Mergers and Acquisitions: Analysis by Type of Biologics

12.4.7.4. Mergers and Acquisitions: Analysis by Type of Biologics and Key Value Drivers

12.5. Key Acquisitions: Deal Multiples

13. RECENT DEVELOPMENTS

13.1. Chapter Overview

13.2. Biopharma Contract Manufacturing Market: Facility Expansions

13.2.1. Cumulative Year-wise Distribution

13.2.2. Analysis by Purpose of Facility Expansion

13.2.3. Analysis by Type of Biologics

13.2.4. Analysis by Type of Biologics and Purpose of Expansion

13.2.5. Analysis by Location of Manufacturing Facility

13.2.6. Regional Analysis

13.2.7. Most Active Players: Analysis by Number of Recent Expansions

13.2.8. Analysis by Headquarters and Purpose

13.2.9. Facility Expansions: Pre-2015 and Post-2015

13.3. Biopharmaceutical Contract Manufacturing Market: Funding Instances

13.4. Technological Advancements

13.4.1. Single Use Technology

13.4.2. Process Analytical Technology (PAT)

13.4.3. Continuous Processing

13.4.3. Quality by Design in Bioprocessing

13.3. Biopharmaceutical Contract Manufacturing Market: Funding Instances

13.4. Technological Advancements

13.4.1. Single Use Technology

13.4.2. Process Analytical Technology

13.4.3. Continuous Processing

13.4.4. Quality by Design in Bioprocessing

14. CAPACITY ANALYSIS

14.1. Chapter Overview

14.2. Assumptions and Methodology

14.3. Biopharmaceutical Contract Manufacturers: Global Production Capacity

14.3.1. Analysis by Size of the CMO

14.3.2. Analysis by Expression Systems

14.3.3. Analysis by Scale of Operation

14.3.4. Analysis by Region

14.3.4.1. Capacity Analysis: North America

14.3.4.2. Capacity Analysis: Europe

14.3.4.3. Capacity Analysis: Asia and Middle East

14.4. Emerging Biologics: Capacity Analysis

14.4.1. ADC Manufacturing Installed Global Capacity: Regional Distribution

14.5. Cell Therapy Manufacturing Capacity: Regional Distribution

14.6. Viral Vectors Installed Manufacturer Capacity: Distribution by Location of Manufacturing Facility

14.7. Concluding Remarks

15. DEMAND ANALYSIS

15.1. Chapter Overview

15.2. Key Assumptions and Methodology

15.3. Overall Annual Demand for Biopharmaceutical Market, 2019-2024

15.3.1. Analysis by Therapeutic Area

15.4. Relationship Between Annual Demand and Capacity

15.5. Demand for Emerging Novel Biologics

15.5.1. ADCs: Overall Annual Demand

15.5.1. ADCs: Demand and Supply Analysis

16. MARKET FORECAST

16.1. Chapter Overview

16.2. Forecast Methodology and Key Assumptions

16.3. Overall Biopharmaceutical Contract Manufacturing Market, 2019-2030

16.3.1. Biopharmaceutical Contract Manufacturing Market for API Manufacturing, 2019-2030

16.3.2. Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, 2019-2030

16.4. Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Expression Systems Used

16.5. Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Scale of Operation

16.6. Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Size of Manufacturers

16.7. Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Geography

16.7.1. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030

16.7.1.1. Biopharmaceutical Contract Manufacturing Market in the US, 2019-2030

16.7.1.2. Biopharmaceutical Contract Manufacturing Market in Canada, 2019-2030

16.7.1.3. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Mammalian Cell-based Operations

16.7.1.4. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Microbial Cell-based Operations

16.7.1.5. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Other Expression System-based Operations

16.7.1.6. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Preclinical / Clinical Scale Operations

16.7.1.7. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Commercial Scale Operations

16.7.1.8. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Small-sized Companies

16.7.1.9. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Mid-sized Companies

16.7.1.10. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Large / Very Large Companies

16.7.2. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030

16.7.2.1. Biopharmaceutical Contract Manufacturing Market in Italy, 2019-2030

16.7.2.2. Biopharmaceutical Contract Manufacturing Market in Germany, 2019-2030

16.7.2.3. Biopharmaceutical Contract Manufacturing Market in France, 2019-2030

16.7.2.4. Biopharmaceutical Contract Manufacturing Market in Spain, 2019-2030

16.7.2.5. Biopharmaceutical Contract Manufacturing Market in the UK, 2019-2030

16.7.2.6. Biopharmaceutical Contract Manufacturing Market in Rest of Europe, 2019-2030

16.7.2.7. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Mammalian Cell-based Operations

16.7.2.8. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Microbial Cell-based Operations

16.7.2.9. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Other Expression System-based Operations

16.7.2.10. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Preclinical / Clinical Operations

16.7.2.11. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Commercial Operations

16.7.2.12. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Small-sized Companies

16.7.2.13. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Mid-sized Companies

16.7.2.14. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Large / Very Large Companies

16.7.3. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030

16.7.3.1. Biopharmaceutical Contract Manufacturing Market in China, 2019-2030

16.7.3.2. Biopharmaceutical Contract Manufacturing Market in India, 2019-2030

16.7.3.3. Biopharmaceutical Contract Manufacturing Market in South Korea, 2019-2030

16.7.3.4. Biopharmaceutical Contract Manufacturing Market in Japan, 2019-2030

16.7.3.5. Biopharmaceutical Contract Manufacturing Market in Australia, 2019-2030

16.7.3.6. Biopharmaceutical Contract Manufacturing Market in Rest of Asia and Other Regions, 2019-2030

16.7.3.7. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Mammalian Cell-based Operations

16.7.3.8. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Microbial Cell-based Operations

16.7.3.9. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Other Expression System-based Operations

16.7.3.10. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Preclinical / Clinical Operations

16.7.3.11. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Commercial Scale Operations

16.7.3.12. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Small-sized Companies

16.7.3.13. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Mid-sized Companies

16.7.3.14. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Large / Very Large Companies

16.7.4 Overall Biopharmaceutical Contract Manufacturing, 2019-2030: Share by Others Segment

17. SWOT ANALYSIS

17.1 Chapter Overview

17.2. Strengths

17.3. Weaknesses

17.4. Opportunities

17.5. Threats

17.6. Comparison of Swot Factors

17.7. Concluding Remarks

18. FUTURE OF THE BIOPHARMACEUTICAL CMO MARKET

18.1. Chapter Overview

18.2. Outsourcing Activities to Witness Significant Growth in the Coming Years

18.3. Shift from One-time Contracts to Strategic Partnerships

18.4. Integration / Adoption of New and Innovative Technologies

18.4.1. Single use Bioreactors

18.4.2. Novel Bioprocess Techniques

18.4.3. Bioprocess Automation

18.5. Focus on Niche Therapeutic Areas

18.6. Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment

18.7. Capability and Expertise Expansions by CMOs to become One Stop Shops

18.8. Offshoring Outsourcing Activities to Maximize Profits and Expand Existing Capacities

18.9. Increase in Financial Inflow and Outsourcing Budgets

18.10. The Need for Humanized Products to Drive the Growth of Mammalian Expression Technologies

18.11. Challenges Faced by both Sponsors and Service Providers

18.11.1. Concerns related to Single Use Systems

18.11.2. Issues Related to Capacity Fluctuations

18.12. Concluding Remarks

19. SURVEY ANALYSIS

19.1. Chapter Overview

19.1.1. Overview of Respondents

19.1.2. Designation of Respondents

19.2. Biologics Manufacturing Expertise

19.3. Scale of Manufacturing

19.4. Location of Production Facilities

19.5. Types of Expression Systems Used

19.6. Types of Bioreactors

19.7. Modes of Operation of Bioreactors

20. INTERVIEW TRANSCRIPTS

20.1. Chapter Overview

20.2. Astrid Brammer, Senior Manager Business Development, Richter-Helm

20.3. Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie

20.4. Christian Bailly, Director of CDMO, Pierre Fabre

20.5. Claire Otjes, Assistant Marketing Manager, Batavia Biosciences

20.6. David C Cunningham, Director Corporate Development, Goodwin Biotechnology

20.7. Dietmar Katinger, Chief Executive Officer, Polymun Scientific

20.8. Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma

20.9. Jeffrey Hung, Chief Commercial Officer, Vigene Biosciences

20.10. Kevin Daley, Director Pharmaceuticals, Novasep

20.11. Mark Wright, Site Head, Grangemouth, Piramal Healthcare

20.12. Nicolas Grandchamp, R&D Leader, GEG Tech

20.13. Raquel Fortunato, Chief Executive Officer, GenIbet Biopharmaceuticals

20.14. Sebastian Schuck, Head of Business Development, Wacker Biotech

20.15. Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies

20.16. Tatjana Buchholz, Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager, Plasmid Factory

20.17. Tim Oldham, Chief Executive Officer, Cell Therapies

21. APPENDIX 1: LIST OF NON-INDUSTRY PLAYERS

22. APPENDIX 2: TABULATED DATA

23. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

Biopharmaceutical contract manufacturing market is projected to grow at an annualized rate of ~8%, till 2030

0 Comments

Curated for You

Popular

Top Contributors more

Latest blog